Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer
Author:
- The International Adjuvant Lung Cancer Trial Collaborative GroupTGThe International Adjuvant Lung Cancer Trial Collaborative Group
Top Cited Papers
- 22 January 2004
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 350 (4) , 351-360
Abstract
On the basis of a previous meta-analysis, the International Adjuvant Lung Cancer Trial was designed to evaluate the effect of cisplatin-based adjuvant chemotherapy on survival after complete resection of non–small-cell lung cancer.Keywords
This publication has 16 references indexed in Scilit:
- Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2003
- Preoperative Chemotherapy Followed by Surgery Compared With Primary Surgery in Resectable Stage I (Except T1N0), II, and IIIa Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2002
- Preoperative chemotherapy for non-small cell lung cancerCancer Treatment Reviews, 2001
- A Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non–Small-Cell Lung CancerNew England Journal of Medicine, 2000
- Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trialsThe Lancet, 1998
- Adjuvant tamoxifen: how long before we know how long?BMJ, 1998
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- A New International Staging System for Lung CancerChest, 1986
- Reporting results of cancer treatmentCancer, 1981
- Repeated assessment of results in clinical trials of cancer treatmentBritish Journal of Radiology, 1971